Cargando…
Germline variants in cancer therapy
Cancer pharmacogenetics implies a complex combination of germline variants from the patient and somatic mutations in tumor cells. Somatic mutations meanwhile have become drugable targets or biomarkers, whereas germline mutations potentially predict adverse drug effects or drug response. Here, we eva...
Autores principales: | Kaehler, Meike, Cascorbi, Ingolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019177/ https://www.ncbi.nlm.nih.gov/pubmed/35582146 http://dx.doi.org/10.20517/cdr.2019.05 |
Ejemplares similares
-
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021) -
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
por: Klümper, Theresa, et al.
Publicado: (2020) -
Limited Impact of 6-Mercaptopurine on Inflammation-Induced Chemokines Expression Profile in Primary Cultures of Enteric Nervous System
por: Kneusels, Jan, et al.
Publicado: (2021) -
Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells
por: Kaehler, Meike, et al.
Publicado: (2022) -
MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells
por: Kaehler, Meike, et al.
Publicado: (2017)